Dr. Saqib Abbasi
Claim this profileUniversity of Kansas Cancer Center
Studies Cancer
Studies Transitional Cell Carcinoma
3 reported clinical trials
10 drugs studied
Area of expertise
1Cancer
Stage IV
Stage III
2Transitional Cell Carcinoma
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Saqib Abbasi is currently running
Eribulin + Chemotherapy
for Bladder Cancer
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.
Recruiting2 awards Phase 3
Blood Test and Immunotherapy
for Bladder Cancer
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, but require an additional treatment called immunotherapy to help prevent their bladder cancer from coming back, can be identified by a blood test. Many types of tumors tend to lose cells or release different types of cellular products including their DNA which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for disease progression or relapse. In this study, a blood test is used to measure ctDNA and see if there is still cancer somewhere in the body after surgery and if giving a treatment will help eliminate the cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and relatlimab, can help the body's immune system to attack the cancer, and can interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine if ctDNA measurement in blood can better identify patients that need additional treatment, if treatment with nivolumab prolongs patients' life and whether the additional immunotherapy treatment with relatlimab extends time without disease progression or prolongs life of bladder cancer patients who have undergone surgical removal of their bladder.
Recruiting1 award Phase 2 & 310 criteria
More about Saqib Abbasi
Clinical Trial Related3 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Saqib Abbasi has experience with
- Eribulin Mesylate
- Docetaxel
- Gemcitabine Hydrochloride
- Paclitaxel
- Avelumab
- Sacituzumab Govitecan
Breakdown of trials Saqib Abbasi has run
Cancer
Transitional Cell Carcinoma
Bladder Cancer
Urothelial Carcinoma
Urethral Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Saqib Abbasi specialize in?
Saqib Abbasi focuses on Cancer and Transitional Cell Carcinoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Saqib Abbasi currently recruiting for clinical trials?
Yes, Saqib Abbasi is currently recruiting for 2 clinical trials in Kansas City Kansas. If you're interested in participating, you should apply.
Are there any treatments that Saqib Abbasi has studied deeply?
Yes, Saqib Abbasi has studied treatments such as Eribulin Mesylate, Docetaxel, Gemcitabine Hydrochloride.
What is the best way to schedule an appointment with Saqib Abbasi?
Apply for one of the trials that Saqib Abbasi is conducting.
What is the office address of Saqib Abbasi?
The office of Saqib Abbasi is located at: University of Kansas Cancer Center, Kansas City, Kansas 66160 United States. This is the address for their practice at the University of Kansas Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.